Precision BioSciences (NASDAQ:DTIL) and Verona Pharma (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.
This is a breakdown of current ratings and target prices for Precision BioSciences and Verona Pharma, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional and Insider Ownership
49.4% of Precision BioSciences shares are held by institutional investors. Comparatively, 67.7% of Verona Pharma shares are held by institutional investors. 14.3% of Precision BioSciences shares are held by insiders. Comparatively, 45.7% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Precision BioSciences and Verona Pharma’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precision BioSciences||$22.24 million||17.44||-$92.88 million||($1.91)||-3.92|
|Verona Pharma||N/A||N/A||-$14.99 million||N/A||N/A|
Verona Pharma has lower revenue, but higher earnings than Precision BioSciences.
Volatility & Risk
Precision BioSciences has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
This table compares Precision BioSciences and Verona Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Precision BioSciences beats Verona Pharma on 6 of the 11 factors compared between the two stocks.
Precision BioSciences Company Profile
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Verona Pharma Company Profile
ArTara Therapeutics, Inc. develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.